Teplizumab - MacroGenics

Drug Profile

Teplizumab - MacroGenics

Alternative Names: hOKT3-gamma-1-ala-ala; hOKT3-γ1-ala-ala; MGA031

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tolerance Therapeutics
  • Developer Immune Tolerance Network; MacroGenics; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health (USA)
  • Class Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 1 diabetes mellitus
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus
  • Discontinued Multiple sclerosis; Psoriasis; Psoriatic arthritis

Most Recent Events

  • 08 Sep 2017 Phase-II development for Type-1 diabetes mellitus (Prevention) is ongoing in USA, Canada and Germany (IV)
  • 15 Dec 2016 Biomarkers information updated
  • 11 May 2015 Teplizumab is still in phase II trials for Type-1 diabetes mellitus (Prevention) in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top